SBTX
NEUTRALSkinBioTherapeutics Appoints New Chief Operating Officer
The healthcare company has appointed a new Chief Operating Officer to its board.
SkinBioTherapeutics
23.75GBX
-6.86%
Market Cap
56.39M
Volume
200k
15% of avg
P/E Ratio
-0.34
EPS (TTM)
-0.7
Beta
1.49
Day Range
0.00p - 0.00p
52 Week Range
0.00p23.75p27.50p
23.75p
SBTX
BADSkinBioTherapeutics Announces Warrant Exercise at Discount
The life science company has announced a warrant exercise at a 21.7% discount to the previous closing price, raising concerns about low demand for its shares.
SBTX
NEUTRALSkinBioTherapeutics Strengthens Board and Leadership Team
The life science company announces changes to its Board and leadership team, including the appointment of a new Chief Operating Officer and Group Finance Director.
SBTX
NEUTRALSkinBioTherapeutics Presents Successful Technical Launch of Zenakine™ at In-Cosmetics Global 2025
The life science company presented its Zenakine™ product at the in-cosmetics global 2025 meeting, receiving a positive response from the audience.
SBTX
NEUTRALSkinBioTherapeutics' Partner Croda Launches Zenakine Skincare Ingredient
The life science company's commercial partner Croda has launched a new skincare ingredient called Zenakine, which is designed to counteract the effects of stress on the skin.
SBTX
NEUTRALSkinBioTherapeutics Announces Holding Change
The biotechnology company has announced a change in its major shareholding.
SBTX
BADSkinBioTherapeutics Raises £0.2M Through Warrant Exercise
The life science company has raised £0.2 million through a warrant exercise, but the 18% discount to the previous share price suggests low investor appetite.
SBTX
NEUTRALSkinBioTherapeutics Announces Warrant Exercise
The life science company announces the exercise of 250,000 warrants, resulting in the issuance of new ordinary shares.
SBTX
NEUTRALSkinBioTherapeutics Sees Increase in Major Shareholder Stake
The biotechnology company has seen an increase in the shareholding of a major investor, but the RNS provides limited additional context.